Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

We undertook a systematic review of 41 randomised studies in disseminated melanoma,
identified by a comprehensive search. We aimed to investigate rates of response to various …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Interleukin-2 (IL-2) is a promising immunotherapeutic agent for the treatment of metastatic
melanoma, acute myelogenous leukemia, and metastatic renal cell carcinoma. While high …

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of
47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural …

Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults,
with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the …

Purpose: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and
interferon alfa-2b (IFN-2b) in multiagent chemotherapy (CT) for advanced melanoma …

Background. No systemic therapy regimen has been recognized as effective for metastatic
mucosal melanoma of the head and neck. We retrospectively analyzed the effectiveness of …

PURPOSE: To examine whether interferon (IFN)-alfa-2a treatment after radiation or
enucleation reduces death rates in patients with uveal melanoma. DESIGN: Interventional …

Malignant melanoma can occur in various ocular structures and accounts for 70% of all
primary eye malignancies. At the time of initial diagnosis of uveal melanoma, most patients …